Shanghai – October 15, 2026 -- WuXi XDC (2268.HK) has won "Best CDMO" at the 2026 World ADC Awards for the fourth consecutive year and "Best CRO" for the second, making it the only contract research, development and manufacturing organization (CRDMO) to take both titles two years running.

Toronto – October 14, 2026 -- Real-world discontinuation of weight-loss medications can reach 67% within 12 months, while clinical trials show sustained weight reduction of 15–22% over 72 weeks, according to materials for an Xtalks webinar featuring Clinical ink executives on October 29.

Bridgewater, N.J. – – October 14, 2026 -- Insmed (Nasdaq: INSM) will present four abstracts on its investigational inhaled therapy treprostinil palmitil inhalation powder (TPIP) at CHEST 2026 in Phoenix, three of them late-breaking, and two ARIKAYCE abstracts at IDWeek 2026 in Washington, D.C. CHEST runs Oct. 18–21 and IDWeek runs Oct. 21–24.

Chief Medical Officer Martina Flammer said the presentations span the company's respiratory portfolio of BRINSUPRI, TPIP and ARIKAYCE.

Indianapolis – October 14, 2026 -- Carnyx Therapeutics Ltd. unveiled CNYX-005, an oral sleep candidate that increased total sleep time by roughly 1.5 to 2 hours in aged rats versus a control arm, as the preclinical-stage company moves toward clinical development.

The increase was driven primarily by more non-rapid eye movement (NREM) sleep. Researchers measured sleep architecture using continuous electroencephalography (EEG) monitoring.

San Diego – – October 14, 2026 -- Global spending on cancer medicines reached $252 billion in 2024 and is forecast to exceed $400 billion by 2028, according to the IQVIA Institute, with the United States accounting for roughly 46% of the total.

About 150 new active substances entered the U.S. oncology market between 2015 and 2024, and launch activity in 2020 to 2024 ran nearly 40% ahead of the prior five years.

Belfast – October 14, 2026 -- Cumulus Neuroscience and Transpharmation Ltd. have formed a strategic partnership to align EEG and behavioral endpoints from preclinical models through first-in-human trials, targeting a therapeutic area where an estimated 6.7% of candidates progress from nonclinical development to FDA approval (Sertkaya et al., JAMA Netw Open, 2024).

Maastricht – October 14, 2026 -- More than half of respondents to the MAPPA patient survey received a primary immunodeficiency (PID) diagnosis after age 18, and 28% reported permanent damage at the time of diagnosis, according to preliminary findings Kedrion Biopharma and AIP APS will present at ESID 2026.

Melbourne – October 14, 2026 -- Telix Pharmaceuticals will present 20 company-related abstracts at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM) in Vienna on October 17-21, 2026. Twelve of them were selected for top-rated oral presentations, with the rest running as ePosters.

Mount Pleasant, S.C. – October 13, 2026 -- Paradigm Therapeutics, Inc. has been named a finalist for the 2026 Prix Galien USA "Best Start-Up" Award, its second consecutive nomination after being a nominee in 2025.

The clinical-stage biopharmaceutical company is developing SD-101 (ZorblesiaTM), a topical cream for wounds and lesions across the entire skin surface in patients with Epidermolysis Bullosa (EB). The Galien Foundation manages the awards, which will be presented on October 29, 2026, at the American Museum of Natural History in New York City.

San Diego – – October 13, 2026 -- Inhibrx Biosciences (Nasdaq: INBX) will present phase 2 data on both clinical-stage candidates in its pipeline in four sessions at three oncology conferences between Oct. 25 and Nov. 20, 2026.